-
Results for the First Quarter 2023
NOK 82.1. The Vascular business segment continues the positive development and grows at 21.5% in NOK, currency neutral 8.8% growth. The Imaging products grow at 9.4% in NOK, currency neutral decline of 3.7%. Currency neutral…
Read more -
Presentation of Medistim’s Q1 2023 Financial Results
The financials will be presented via a live webinar on Tuesday, April 25th from 08:00-09:00 (CEST). Representatives for the company will be Kari Eian Krogstad (CEO), and Thomas Jakobsen (CFO). The recording will be made available on…
Read more -
Medistim is opening a direct sales office in China
More than 60,000 coronary bypass procedures are performed in China annually and the number is expected to continue to grow high single digit in the years to come. Today, about 70% of these procedures are…
Read more -
Annual Report 2022
Further supported by several high-quality symposia at the largest heart surgery conferences, we achieved 44 % growth in the imaging product portfolio in 2022. And while steadily penetrating the Cardiac bypass market, we also build…
Read more -
Medistim Expands Market Coverage in Canada by Going Direct
“We are excited to announce this strategic move that will strengthen our relationship with our customers in Canada and grow our business there,” – Medistim President and CEO Kari E. Krogstad
Read more -
Results for the Fourth Quarter and Preliminary Results for 2022
All major geographical regions drive sales growth. Currency-neutral sales increased by 21.6 % for the quarter and 11.9 % for the year. Currency-neutral sales of own products increase 24.6 % for the quarter and 14.0…
Read more -
Capital Markets Day
See the recording from Medistim's Capital Markets Day on March 21st where two international thought leaders, Professors John. D. Puskas and Pirkka Vikatmaa shared their insights on the future trends in Cardiac and Vascular Surgery…
Read more -
Presentation of Medistim’s Q4 and preliminary year-end results 2022
The financials will be presented via a live webinar on Wednesday, March 1st from 08:00-09:00 (CET). Representatives for the company will be Kari Eian Krogstad (CEO), and Thomas Jakobsen (CFO). The recording will be made available…
Read more -
Medistim celebrates a long-standing relationship with the Japanese cardiac surgery community
“This is very much a story of a perfect fit between Norwegian technology and Japanese quality standards. Medistim technology has been able to meet expectations of the quality driven Japanese market. There are few arenas…
Read more -
Results for the third quarter 2022
In the third quarter, total revenue ended at MNOK 116.5 (MNOK 102.1), a 14.0% increase. Sales growth is driven by the USA with a currency-neutral sales increase of 18.7 % for the quarter and 24.1…
Read more
PC: Hold CTRL and press + (plus) to enlarge or - (minus) to shrink.
MAC: Hold CMD and press + (plus) to enlarge or - (minus) to shrink.